Romilkimab – a novel engineered, humanized immunoglobulin(Ig)-G4 antibody – delivers significant skin benefits for individuals with early diffuse cutaneous systemic sclerosis (dcSSc), a subtype of SSc, a phase II proof-of-concept study has shown.
The efficacy and safety of long-term tildrakizumab are comparable and maintained without evidence of reduced durability of response through 148 weeks of treatment in patients with and without metabolic syndrome (MetS), results from two phase III trials have shown.
There is a high burden of paediatric eczema in the primary care setting. Dr Liew Hui Min, a consultant dermatologist from SOG-HM Liew Skin & Laser Clinic at Gleneagles Hospital, Singapore, shares her insights with Pearl Toh on how to manage paediatric eczema in the primary care setting.
Upadacitinib monotherapy improved symptoms and quality of life (QoL) in adolescents and adults with moderate-to-severe atopic dermatitis (AD), according to the phase III Measure Up 1 and 2 studies presented at EADV 2020.
The novel, humanized IgG1 monoclonal antibody risankizumab was superior to ustekinumab and placebo in reducing and potentially eliminating symptoms of moderate-to-severe chronic plaque psoriasis, according to two replicate phase III trials.
The oral Janus kinase (JAK) 1/2 inhibitor baricitinib showed potential as an add-on to background topical corticosteroids (TCS) for treating moderate-to-severe atopic dermatitis (AD) that does not respond well to TCS alone, the phase III BREEZE-AD7 trial suggests.
Treatment with low-dose (LD) or high-dose (HD) secukinumab significantly improved Psoriasis Area and Severity Index (PASI)* scores in paediatric patients with severe chronic plaque psoriasis, according to a study presented at EADV 2020.
Adjuvant therapy with the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib for 12 months led to long-term relapse-free survival (RFS) with no apparent long-term toxicities in patients with resected stage III melanoma with BRAF V600E or V600K mutations, according to the extended follow-up results of the phase III COMBI-AD* trial.
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa,
08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
Spending too much time sitting cannot be good for the body, and rising to one's feet breaks up such a behaviour and yields small, but meaningful, reductions in certain cardiovascular disease (CVD) risk factors, according to the results of a meta-analysis.
Use of thyroid hormone therapy does not seem to protect older adults with subclinical hypothyroidism against mortality, but it appears to confer survival benefits to those aged <65 years, results of a study have shown.